Arcturus Therapeutics Holdings (ARCT)
(Delayed Data from NSDQ)
$26.55 USD
+0.38 (1.45%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $26.51 -0.04 (-0.15%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Income Statements
Fiscal Year end for Arcturus Therapeutics Holdings Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 167 | 206 | 12 | 10 | 21 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 167 | 206 | 12 | 10 | 21 |
Selling & Adminstrative & Depr. & Amort Expenses | 245 | 194 | 215 | 81 | 46 |
Income After Depreciation & Amortization | -78 | 12 | -203 | -72 | -26 |
Non-Operating Income | 34 | -1 | 1 | 0 | 0 |
Interest Expense | -17 | 0 | 2 | 0 | 0 |
Pretax Income | -28 | 11 | -204 | -72 | -26 |
Income Taxes | 2 | 1 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -30 | 9 | -204 | -72 | -26 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -30 | 9 | -204 | -72 | -26 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -75 | 14 | -202 | -71 | -25 |
Depreciation & Amortization (Cash Flow) | 3 | 2 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -78 | 12 | -203 | -72 | -26 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 26.63 | 27.09 | 26.32 | 20.31 | 12.07 |
Diluted EPS Before Non-Recurring Items | -1.99 | 0.35 | -7.74 | -3.55 | -2.15 |
Diluted Net EPS (GAAP) | -1.12 | 0.35 | -7.74 | -3.55 | -2.15 |
Fiscal Year end for Arcturus Therapeutics Holdings Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 30.86 | 45.14 | 10.52 | 80.29 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 30.86 | 45.14 | 10.52 | 80.29 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 49.13 | 64.46 | 65.90 | 65.53 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -18.27 | -19.32 | -55.38 | 14.76 |
Non-Operating Income | NA | -0.05 | 0.00 | 0.15 | 33.63 |
Interest Expense | NA | -6.88 | -3.98 | -3.25 | -2.48 |
Pretax Income | NA | -11.45 | -15.33 | -51.97 | 50.86 |
Income Taxes | NA | 0.26 | 0.89 | 0.58 | 0.10 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -11.71 | -16.22 | -52.55 | 50.75 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -11.71 | -16.22 | -52.55 | 50.75 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 26.63 | 26.57 | 26.56 | 27.15 |
Diluted EPS Before Non-Recurring Items | NA | -0.32 | -0.61 | -1.98 | 0.88 |
Diluted Net EPS (GAAP) | NA | -0.40 | -0.61 | -1.98 | 1.87 |